(Q31138894)

29 June 2017

0 references

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis (English)

1 reference

29 June 2017

0 references

0 references

Gauthier S

1

1 reference

29 June 2017

Loft H

series ordinal

2

1 reference

29 June 2017

Cummings J

series ordinal

3

1 reference

29 June 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

International Journal of Geriatric Psychiatry

29 June 2017

1 reference

29 June 2017

23

1 reference

29 June 2017

5

1 reference

29 June 2017

537-545

1 reference

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

29 June 2017

1 reference

The course of psychopathologic features in mild to moderate Alzheimer disease.

21 January 2018

1 reference

Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates

21 January 2018

1 reference

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.

21 January 2018

1 reference

7 January 2021

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

1 reference

7 January 2021

Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.

1 reference

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

7 January 2021

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

7 January 2021

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

1 reference

7 January 2021

Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis

1 reference

7 January 2021

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

1 reference

7 January 2021

A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease.

1 reference

7 January 2021

Psychopathological features in Alzheimer's disease: course and relationship with cognitive status.

1 reference

7 January 2021

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

1 reference

7 January 2021

The incremental direct costs associated with behavioral symptoms in AD.

1 reference

7 January 2021

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

7 January 2021

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

7 January 2021

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

1 reference

7 January 2021

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

1 reference

7 January 2021

Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction

1 reference

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

7 January 2021

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

1 reference

7 January 2021

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

7 January 2021

Patient and caregiver characteristics and nursing home placement in patients with dementia

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.1949

1 reference

29 June 2017

1 reference